Filtered By:
Drug: Methotrexate
This page shows you your search results in order of date. This is page number 5.
Order by Relevance | Date
Total 289 results found since Jan 2013.
Safety of Methotrexate in Chronic Urticaria Unresponsive to Omalizumab
Iran J Allergy Asthma Immunol. 2021 Aug 7;20(4):500-504.ABSTRACTOmalizumab (humanized anti-immunoglobulin IgE) is currently the first choice of treatment for chronic urticaria refractory to high-dose second-generation antihistamines (sgAH). Despite its high safety profile, response to omalizumab is insufficient in one-third of patients. Some studies have suggested that methotrexate is effective in antihistamine-refractory chronic urticaria, but there are no studies on its efficacy and safety in patients unresponsive to omalizumab. This retrospective study aimed to investigate the clinical effectiveness and adverse effects ...
Source: Iranian Journal of Allergy, Asthma and Immunology - August 22, 2021 Category: Allergy & Immunology Authors: Mehmet Unsel Source Type: research
28700 Chromate-induced allergic contact dermatitis treated with dupilumab
Chromate is a common cause of irritant and allergic contact dermatitis in occupational workers who handle work cement. Chromate allergy presents as a persistent dermatitis and is considered to have a relatively poor prognosis, often with therapeutic recalcitrance. When therapeutics such as topical corticosteroids, topical calcineurin inhibitors, and immune-modulating treatments like methotrexate fail, patients are advised that avoidance may be the only remaining option —an option that is particularly challenging if the patient’s occupation necessitates chromate exposure.
Source: Journal of the American Academy of Dermatology - August 8, 2021 Category: Dermatology Authors: Britney N. Wilson, Esther A. Balogh, David J. Rayhan, Daniel J. Yousefzadeh, Steven R. Feldman Source Type: research
STELARA ® (ustekinumab) Demonstrated Sustained Symptomatic and Corticosteroid-Free Remission Rates in Adults with Moderately to Severely Active Ulcerative Colitis at Nearly Three Years in Long-Term Extension of Phase 3 Trial
SPRING HOUSE, PENNSYLVANIA, July 9, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new three-year data from the long-term extension (LTE) of the STELARA® (ustekinumab) Phase 3 UNIFI study. The data demonstrated the majority (55.2 percent) of adult patients with moderately to severely active ulcerative colitis (UC) who initially responded to treatment with STELARA sustained symptomatic remissiona rates at nearly three years (week 152).1 Furthermore, a majority (96.4 percent) of the patients in symptomatic remissiona at week 152 were corticosteroid-free. These data are being presented...
Source: Johnson and Johnson - July 9, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Janssen Presents Results of First Head-to-Head Study of Biologic Therapies in Patients with Moderate to Severe Crohn ’s Disease
SPRING HOUSE, PENNSYLVANIA, May 23, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced efficacy and safety data for STELARA® (ustekinumab) in Crohn’s disease (CD) and ulcerative colitis (UC),1-4including data from the SEAVUE study, the first head-to-head study of biologic therapies in patients with CD, presented in a Clinical Science Late-Breaking Abstract Plenary session.1 SEAVUE data showed treatment with STELARA demonstrated high rates of clinical remission, corticosteroid-free remission, clinical response and endoscopic response through one year in biologic-naïve patients with mo...
Source: Johnson and Johnson - May 24, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
COVID-19 Vaccination in Patients with Autoimmune Inflammatory Rheumatic Diseases: Clinical Guidance of the Korean College of Rheumatology
J Korean Med Sci. 2021 Mar 29;36(12):e95. doi: 10.3346/jkms.2021.36.e95.ABSTRACTThe coronavirus disease 2019 (COVID-19) pandemic has caused more than 100 million infections and 2 million deaths worldwide. In up to 20% of cases, COVID-19 infection can take a severe, life-threatening course. Therefore, preventive measures such as mask-wearing, hand hygiene, and social distancing are important. COVID-19 vaccines that use novel vaccine technology can prevent up to 95% of infections. However, the uncertainty regarding the efficacy and safety of vaccination in patients with autoimmune inflammatory rheumatic disease (AIIRD), who ...
Source: J Korean Med Sci - March 30, 2021 Category: General Medicine Authors: Jin Kyun Park Eun Bong Lee Kichul Shin Yoon Kyoung Sung Tae Hwan Kim Seong Ryul Kwon Myeung Su Lee Seung Jae Hong Byoong Yong Choi Shin Seok Lee Han Joo Back Korean College of Rheumatology Task Force for COVID-19 Vaccine Guidance for Patients with Autoimm Source Type: research
